Skip to main content

Advertisement

Log in

Insomnia in Elderly Patients: Recommendations for Pharmacological Management

  • Review Article
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Chronic insomnia affects 57% of the elderly in the United States, with impairment of quality of life, function, and health. Chronic insomnia burdens society with billions of dollars in direct and indirect costs of care. The main modalities in the treatment of insomnia in the elderly are psychological/behavioral therapies, pharmacological treatment, or a combination of both. Various specialty societies view psychological/behavioral therapies as the initial treatment intervention. Pharmacotherapy plays an adjunctive role when insomnia symptoms persist or when patients are unable to pursue cognitive behavioral therapies. Current drugs for insomnia fall into different classes: orexin agonists, histamine receptor antagonists, non-benzodiazepine gamma aminobutyric acid receptor agonists, and benzodiazepines. This review focuses on Food and Drug Administration (FDA)-approved drugs for insomnia, including suvorexant, low-dose doxepin, Z-drugs (eszopiclone, zolpidem, zaleplon), benzodiazepines (triazolam, temazepam), and ramelteon. We review the indications, dosing, efficacy, benefits, and harms of these drugs in the elderly, and discuss data on drugs that are commonly used off-label to treat insomnia, and those that are in clinical development. The choice of a hypnotic agent in the elderly is symptom-based. Ramelteon or short-acting Z-drugs can treat sleep-onset insomnia. Suvorexant or low-dose doxepin can improve sleep maintenance. Eszopiclone or zolpidem extended release can be utilized for both sleep onset and sleep maintenance. Low-dose zolpidem sublingual tablets or zaleplon can alleviate middle-of-the-night awakenings. Benzodiazepines should not be used routinely. Trazodone, a commonly used off-label drug for insomnia, improves sleep quality and sleep continuity but carries significant risks. Tiagabine, sometimes used off-label for insomnia, is not effective and should not be utilized. Non-FDA-approved hypnotic agents that are commonly used include melatonin, diphenhydramine, tryptophan, and valerian, despite limited data on benefits and harms. Melatonin slightly improves sleep onset and sleep duration, but product quality and efficacy may vary. Tryptophan decreases sleep onset in adults, but data in the elderly are not available. Valerian is relatively safe but has equivocal benefits on sleep quality. Phase II studies of dual orexin receptor antagonists (almorexant, lemborexant, and filorexant) have shown some improvement in sleep maintenance and sleep continuity. Piromelatine may improve sleep maintenance. Histamine receptor inverse agonists (APD-125, eplivanserin, and LY2624803) improve slow-wave sleep but, for various reasons, the drug companies withdrew their products.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. F. Scott Fitzgerald Sayings and Quotes. http://www.wiseoldsayings.com/authors/f.-scott-fitzgerald-quotes/. Accessed 25 Mar 2018.

  2. Roth T. New developments for treating sleep disorders. J Clin Psychiatry. 2001;62(suppl):10:3–4

  3. Mellinger GD, Balter MB, Uhlenhuth EH. Insomnia and its treatment. Prevalence and correlates. Arch Gen Psychiatry. 1985;42:225–32.

    Article  PubMed  CAS  Google Scholar 

  4. Schutte-Rodin S, Broch L, Buysse D, et al. Clinical guideline for the evaluation and chronic management of chronic insomnia in adults. J Clin Sleep Med. 2008;4:487–504.

    PubMed  PubMed Central  Google Scholar 

  5. Foley DJ, Monjan AA, Brown L, et al. Sleep complaints among elderly persons: an epidemiologic study of three communities. Sleep. 1995;18:425–32.

    Article  PubMed  CAS  Google Scholar 

  6. Sleep Poll Executive Summary. https://sleepfoundation.org/sites/default/files/2003SleepPollExecSumm.pdf. Accessed 01 Jun 2017.

  7. Foley DJ, Monian A, Simonsick EM, et al. Incidence and remission of insomnia among elderly adults: an epidemiologic study of 6800 persons over three years. Sleep. 1999;22:S366–72.

    PubMed  Google Scholar 

  8. Ohayon MM, Vecchierini MF, Lubin S. Relationship between daytime sleepiness and cognitive functioning in an elderly population. J Sleep Res. 2000;9:143.

    Google Scholar 

  9. Henderson S, Jorm AF, Scott LR, et al. Insomnia in the elderly: its prevalence and correlates in the general population. Med J Aust. 1995;162:22–4.

    PubMed  CAS  Google Scholar 

  10. Brabbins CJ, Dewey ME, Copeland JRM, et al. Insomnia in the elderly: prevalence, gender differences and relationships with morbidity and mortality. Int J Geriatr Psychiatry. 1993;8:473–80.

    Article  Google Scholar 

  11. Maggi S, Langlois JA, Minicuci N, et al. Sleep complaints in community- dwelling older persons: prevalence, associated factors, and reported causes. J Am Geriatr Soc. 1998;46:161–8.

    Article  PubMed  CAS  Google Scholar 

  12. Chiu HF, Leung T, Lam LC, et al. Sleep problems in Chinese elderly in Hong Kong. Sleep. 1999;22:717–26.

    Article  PubMed  CAS  Google Scholar 

  13. Sukying C, Bhokakul V, Udomsubpayakul U. An epidemiological study on insomnia in an elderly Thai population. J Med Assoc Thai. 2003;86:316–24.

    PubMed  Google Scholar 

  14. Mallon L, Hetta J. A survey of sleep habits and sleeping difficulties in an elderly Swedish population. Ups J Med Sci. 1997;102:185–97.

    Article  PubMed  CAS  Google Scholar 

  15. Ellis JG, Perlis ML, Neale LF, et al. The natural history of insomnia: focus on prevalence and incidence of acute insomnia. J Psychiatr Res. 2012;46:1278–85.

    Article  PubMed  Google Scholar 

  16. Gooneratne N. Treatment epidemiology. J Clin Sleep Med. 2005;1:e477–9.

    Google Scholar 

  17. Balkrishnan R, Rasu R, Rajagopalan R. Physician and patient determinants of pharmacologic treatment of sleep difficulties in outpatient settings in the United States. Sleep. 2005;28(6):715–9.

    Article  PubMed  Google Scholar 

  18. Sateia MJ, Buysse DJ, Krystal AD, et al. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med. 2017;13:307–49. https://doi.org/10.5664/jcsm.6470.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Ohayon MM, Carskadon MA, Guilleminault C, et al. Meta-analysis of quantitative sleep parameters from childhood to old age in healthy individuals: developing normative sleep values across the human lifespan. Sleep. 2004;27:1255–73.

    Article  PubMed  Google Scholar 

  20. Mander BA, Winer JR, Walker MP. Sleep and human aging. Neuron. 2017;94:19–36. https://doi.org/10.1016/j.neuron.2017.02.004.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  21. Gureje O, Kola L, Ademola A, Olley BO. Profile, comorbidity and impact of insomnia in the Ibadan study of ageing. Int J Geriatr Psychiatry. 2009;24(686–93):80.

    Google Scholar 

  22. Stone KL, Ensrud KE, Ancoli-Israel S. Sleep, insomnia and falls in elderly patients. Sleep Med. 2008;9:S18–22.

    Article  PubMed  Google Scholar 

  23. Avidan AY, Fries BE, James ML, et al. Insomnia and hypnotic use, recorded in the minimum data set, as predictors of falls and hip fractures in Michigan nursing homes. J Am Geriatr Soc. 2005;53:955–62.

    Article  PubMed  Google Scholar 

  24. Ancoli-Israel S, Cooke JR. Prevalence and comorbidity of insomnia and effect on functioning in elderly populations. J Am Geriatr Soc. 2005;53:S264–71.

    Article  PubMed  Google Scholar 

  25. Haimov I, Hanuka E, Horowitz Y. Chronic insomnia and cognitive functioning among older adults. Behav Sleep Med. 2008;6:32–54. https://doi.org/10.1080/15402000701796080.

    Article  PubMed  Google Scholar 

  26. Cricco M, Simonsick EM, Foley DJ. The impact of insomnia on cognitive functioning in older adults. J Am Geriatr Soc. 2001;49:1185–9.

    Article  PubMed  CAS  Google Scholar 

  27. Johar H, Kawan R, Emeny RT, Ladwig KH. Impaired sleep predicts cognitive decline in old people: findings from the prospective KORA age study. Sleep. 2016;39:217–26. https://doi.org/10.5665/sleep.5352.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Blackwell T, Yaffe K, Laffan A, et al. Associations of objectively and subjectively measured sleep quality with subsequent cognitive decline in older community-dwelling men: the MrOS sleep study. Sleep. 2014;37:655–63.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Blackwell T, Yaffe K, Ancoli-Israel S, et al. Poor sleep is associated with impaired cognitive function in older women: the study of osteoporotic fractures. J Gerontol A Biol Sci Med Sci. 2006;61:405–10.

    Article  PubMed  Google Scholar 

  30. de Almondes KM, Costa MV, Malloy-Diniz LF. Diniz BS 2016 Insomnia and risk of dementia in older adults: systematic review and meta-analysis. J Psychiatr Res. 2016;77(109–15):8. https://doi.org/10.1016/j.jpsychires.2016.02.021 (Epub Epub 2016 Mar 8).

    Article  Google Scholar 

  31. Kalmbach DA, Pillai V, Arnedt JT, Drake CL. DSM-5 insomnia and short sleep: comorbidity landscape and racial disparities. Sleep. 2016;39:2101–11. https://doi.org/10.5665/sleep.6306.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Taylor DJ, Lichstein KL, Durrence HH. Insomnia as a health risk factor. Behav Sleep Med. 2003;1:227–47.

    Article  PubMed  Google Scholar 

  33. Wingard DL, Berkman LF. Mortality risk associated with sleeping patterns among adults. Sleep. 1983;6:102–7.

    Article  PubMed  CAS  Google Scholar 

  34. Laugsand LE, Vatten LJ, Platou C, Janszky I. Insomnia and the risk of acute myocardial infarction: a population study. Circulation. 2011;124:2073–81.

    Article  PubMed  Google Scholar 

  35. Nakazaki C, Noda A, Koike Y, et al. Association of insomnia and short sleep duration with atherosclerosis risk in the elderly. Am J Hypertens. 2012;25:1149–55. https://doi.org/10.1038/ajh.2012.107 (Epub 2012 Aug 2).

    Article  PubMed  Google Scholar 

  36. Chilcott LA, Shapiro CM. The socioeconomic impact of insomnia. An overview. Pharmacoeconomics. 1996;10(Suppl 1):1–14.

    Article  PubMed  Google Scholar 

  37. Stoller MK. Economic effects of insomnia. Clin Ther. 1994;16:873–97.

    PubMed  CAS  Google Scholar 

  38. Walsh JK. Clinical and socioeconomic correlates of insomnia. J Clin Psychiatry. 2004;65(Suppl 8):13–9.

    PubMed  Google Scholar 

  39. Daley M, Morin CM, LeBlanc M, et al. The economic burden of insomnia: direct and indirect costs for individuals with insomnia syndrome, insomnia symptoms, and good sleepers. Sleep. 2009;32:55–64.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Leger D, Levy E, Paillard M. The direct costs of insomnia in France. Sleep. 1999;22:S394–401.

    PubMed  Google Scholar 

  41. Ozminkowski RJ, Wang S, Walsh JK. The direct and indirect costs of untreated insomnia in adults in the United States. Sleep. 2007;30:263–73.

    Article  PubMed  Google Scholar 

  42. Morin CM, Bootzin RR, Buysse DJ, et al. Psychological and behavioral treatment of insomnia: update of the recent evidence (1998–2004). Sleep. 2006;29:1398–414.

    Article  PubMed  Google Scholar 

  43. Bonnet MH, Arand DL. Overview of insomnia in adults. Treatment of insomnia in adults. In: UpToDate, Benca R, Eichler AF, editors. Walthan, MA. Accessed on 05 Nov 2017.

  44. Qaseem A, Kansagara D, Forciea MA, Cooke M, Denberg TD. Clinical Guidelines Committee Of The American College Of Physicians. Management of chronic insomnia disorder in adults: a clinical practice guideline from the American College Of Physicians. Ann Intern Med. 2016;165(2):125–33. https://doi.org/10.7326/M15-2175 (Epub 2016 May 3).

    Article  PubMed  Google Scholar 

  45. Wilt TJ, MacDonald R, Brasure M, et al. Pharmacologic treatment of insomnia disorder: an evidence report for a clinical practice guideline by the American College of Physicians. Ann Intern Med. 2016;165:103–12. https://doi.org/10.7326/m15-1781 (Epub 2016 May 3. Review).

    Article  PubMed  Google Scholar 

  46. Wilson SJ, Nutt DJ, Alford C, et al. British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders. J Psychopharmacol. 2010;24:1577–600.

    Article  PubMed  CAS  Google Scholar 

  47. Bain KT. Management of chronic insomnia in elderly persons. Am J Geriatr Pharmacother. 2006;4:168–92.

    Article  PubMed  CAS  Google Scholar 

  48. McCall WV. Sleep in the elderly: burden, diagnosis, and treatment. Prim Care Companion J Clin Psychiatry. 2004;6:9–20.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Bloom HG, Ahmed I, Alessi CA, et al. Evidence-based recommendations for the assessment and management of sleep disorders in older persons. J Am Geriatr Soc. 2009;57:761–89.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Riemann D, Baglioni C, Bassetti C, et al. European guideline for the diagnosis and treatment of insomnia. J Sleep Res. 2017;26:675–700.

    Article  PubMed  Google Scholar 

  51. Glass J, Lanctôt KL, Herrmann N et al. Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. BMJ. 2005;19: 331(7526):1169 (Epub 2005 Nov 11).

  52. Kay-Stacey M, Attarian H. Advances in the management of chronic insomnia. BMJ. 2016;354:i2123. https://doi.org/10.1136/bmj.i2123.

    Article  PubMed  Google Scholar 

  53. Schroeck JL, Ford J, Conway EL, et al. Review of safety and efficacy of sleep medicines in older adults. Clin Ther. 2016;38:2340–72. https://doi.org/10.1016/j.clinthera.2016.09.010 (Epub 2016 Oct 15).

    Article  PubMed  CAS  Google Scholar 

  54. Cheung JMY, Bartlett DJ, Armour CL, et al. Treating insomnia: a review of patient perceptions toward treatment. Behav Sleep Med. 2016;14:235–66. https://doi.org/10.1080/15402002.2014.981818.

    Article  PubMed  Google Scholar 

  55. Morin CM, Gaulier B, Barry T, et al. Patients’ acceptance of psychological and pharmacological therapies for insomnia. Sleep. 1992;15(4):302–5.

    Article  PubMed  CAS  Google Scholar 

  56. Sidani S, Epstein DR, Bootzin R, et al. Assessment of preferences for treatment: validation of a measure. Res Nurs Health. 2009;32:419–31.

    Article  PubMed  PubMed Central  Google Scholar 

  57. NIH State of the Science Conference statement on manifestations and management of chronic insomnia in adults statement. NIH Consens State Sci Statements. J Clin Sleep Med. 2005;1(4):412–21.

    Google Scholar 

  58. Black DS, O’Reilly GA, Olmstead R, et al. Mindfulness meditation and improvement in sleep quality and daytime impairment among older adults with sleep disturbances: a randomized clinical trial. JAMA Intern Med. 2015;175:494–501.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Morin CM, Colecchi C, Stone J, et al. Behavioral and pharmacological therapies for late-life insomnia: a randomized controlled trial. JAMA. 1999;281:991–9.

    Article  PubMed  CAS  Google Scholar 

  60. Sivertsen B, Omvik S, Pallesen S, et al. Cognitive behavioral therapy vs zopiclone for treatment of chronic primary insomnia in older adults: a randomized controlled trial. JAMA. 2006;295:2851–8. https://doi.org/10.1001/jama.295.24.2851.

    Article  PubMed  Google Scholar 

  61. Omvik S, Sivertsen B, Pallesen S, et al. Daytime functioning in older patients suffering from chronic insomnia: treatment outcome in a randomized controlled trial comparing CBT with zopiclone. Behav Res Ther. 2008;46:623–41. https://doi.org/10.1016/j.brat.2008.02.013.

    Article  PubMed  Google Scholar 

  62. Irwin MR, Olmstead R, Carrillo C, et al. Cognitive behavioral therapy vs. Tai Chi for late life insomnia and inflammatory risk: a randomized controlled comparative efficacy trial. Sleep. 2014;37:1543–52. https://doi.org/10.5665/sleep.4008.

    Article  PubMed  PubMed Central  Google Scholar 

  63. Lovato N, Lack L, Wright H, et al. Evaluation of a brief treatment program of cognitive behavior therapy for insomnia in older adults. Sleep. 2014;37:117–26. https://doi.org/10.5665/sleep.3320.

    Article  PubMed  PubMed Central  Google Scholar 

  64. Rybarczyk B, Stepanski E, Fogg L, et al. A placebo-controlled test of cognitive-behavioral therapy for comorbid insomnia in older adults. J Consult Clin Psychol. 2005;73:1164–74.

    Article  PubMed  Google Scholar 

  65. Morin CM, Kowatch RA, Barry T, et al. Cognitive-behavior therapy for late-life insomnia. J Consult Clin Psychol. 1993;61:137–46.

    Article  PubMed  CAS  Google Scholar 

  66. Morgan K, Gregory P, Tomeny M, et al. Self-help treatment for insomnia symptoms associated with chronic conditions in older adults: a randomized controlled trial. J Am Geriatr Soc. 2012;60:1803–10. https://doi.org/10.1111/j.1532-5415.2012.04175.x.

    Article  PubMed  Google Scholar 

  67. Buysse DJ. Insomnia. JAMA. 2013;309:706–16. https://doi.org/10.1001/jama.2013.193.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  68. Brasure M, Fuchs E, McDonald R, et al. Psychological and Behavioral Interventions for Managing Insomnia Disorder: An Evidence Report for a Clinical Practice Guideline by the American College of Physicians. Ann Intern Med. 2016;165:113–24. https://doi.org/10.7326/m15-1782 (Epub 2016 May 3).

    Article  PubMed  Google Scholar 

  69. Buysse DJ, Germain A, Moul DE, et al. Efficacy of brief behavioral treatment for chronic insomnia in older adults. Arch Intern Med. 2011;171:887–95.

    Article  PubMed  PubMed Central  Google Scholar 

  70. McCrae CS, McGovern R, Lukefahr R, et al. Research evaluating brief behavioral sleep treatments for rural elderly (RESTORE): a preliminary examination of effectiveness. Am J Geriatr Psychiatry. 2007;15:979–82.

    Article  PubMed  Google Scholar 

  71. Soeffing JP, Lichstein KL, Nau SD, et al. Psychological treatment of insomnia in hypnotic- dependent older adults. Sleep Med. 2008;9:165–71.

    Article  PubMed  Google Scholar 

  72. Alessi C, Vitiello MV. Insomnia (primary) in older people: non-drug treatments. BMJ Clin Evid. 2015;2015:2302.

    PubMed  PubMed Central  Google Scholar 

  73. Chan WS, Williams J, Dautovich ND, et al. Night-to-night sleep variability in older adults with chronic insomnia: mediators and moderators in a randomized controlled trial of brief behavioral therapy (BBT-I). J Clin Sleep Med. 2017;13:1243–54. https://doi.org/10.5664/jcsm.6790.

    Article  PubMed  PubMed Central  Google Scholar 

  74. Lichstein KL, Scogin F, Thomas SJ, et al. Telehealth cognitive behavior therapy for co-occurring insomnia and depression symptoms in older adults. J Clin Psychol. 2013;69:1056–65. https://doi.org/10.1002/jclp.22030.

    Article  PubMed  PubMed Central  Google Scholar 

  75. Seyffert M, Lagisetty P, Landgraf J, et al. Internet-delivered cognitive behavioral therapy to treat insomnia: a systematic review and meta-analysis. PLoS One. 2016;11:e0149139. https://doi.org/10.1371/journal.pone.0149139 (eCollection 2016).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  76. Rybarczyk B, Mack L, Harris JH, et al. Testing two types of self-help CBT-I for insomnia in older adults with arthritis or coronary artery disease. Rehabil Psychol. 2011;56:257–66. https://doi.org/10.1037/a0025577.

    Article  PubMed  Google Scholar 

  77. Koffel E, Kuhn E, Petsoulis N, et al. A randomized controlled pilot study of CBT-I Coach: feasibility, acceptability, and potential impact of a mobile phone application for patients in cognitive behavioral therapy for insomnia. Health Inf J. 2018;24:3–13. https://doi.org/10.1177/1460458216656472 (Epub 2016 Jun 27).

    Article  Google Scholar 

  78. Rochon PA. Drug prescribing for older adults. In: UpToDate, Schmader KE, Sullivan DJ, editors. Walthan, MA. Accessed on 06 Dec 2017.

  79. Brenner GM, Stevens CW. Sedative-hypnotic and anxiolytic drugs. In: Brenner GM, Stevens CW, editors. Brenner and Stevens pharmacology. Philadelphia: Elsevier; 2018. p. 205–16.

    Google Scholar 

  80. Wilckens KA, Hall MH, Nebes RD, et al. Changes in cognitive performance are associated with changes in sleep in older adults with insomnia. Behav Sleep Med. 2016;14:295–310. https://doi.org/10.1080/15402002.2014.1002034 Epub 2015 Aug 31.

    Article  PubMed  Google Scholar 

  81. Blackwell T, Yaffe K, Ancoli-Israel S, et al. Osteoporotic Fractures in Men (MrOS) Study Group. Association of sleep characteristics and cognition in older community-dwelling men: the MrOS sleep study. Sleep. 2011;34:1347–56. https://doi.org/10.5665/sleep.1276.

    Article  PubMed  PubMed Central  Google Scholar 

  82. Devore EE, Grodstein F, Schernhammer ES. Sleep duration in relation to cognitive function among older adults: a systematic review of observational studies. Neuroepidemiology. 2016;46:57–78. https://doi.org/10.1159/000442418 (Epub 2016 Jan 7. Review).

    Article  PubMed  Google Scholar 

  83. Fogel S, Vien C, Karni A, et al. Sleep spindles: a physiological marker of age-related changes in gray matter in brain regions supporting motor skill memory consolidation. Neurobiol Aging. 2017;49:154–64. https://doi.org/10.1016/j.neurobiolaging.2016.10.009 (Epub 2016 Oct 11).

    Article  PubMed  Google Scholar 

  84. Ackermann S, Rasch B. Differential effects of non-REM and REM sleep on memory consolidation? Curr Neurol Neurosci Rep. 2014;14:430. https://doi.org/10.1007/s11910-013-0430-8.

    Article  PubMed  Google Scholar 

  85. Guilleminault C, Davis K, Huynh NT. Prospective randomized study of patients with insomnia and mild sleep disordered breathing. Sleep. 2008;31(11):1527–33.

    Article  PubMed  PubMed Central  Google Scholar 

  86. Guilleminault C, Palombini L, Poyares D, Chowdhuri S. Chronic insomnia, postmenopausal women, and sleep disordered breathing: part 1. Frequency of sleep disordered breathing in a cohort. J Psychosom Res. 2002;53(1):611–5.

    Article  PubMed  Google Scholar 

  87. Luyster FS, Buysse DJ, Strollo PJ. Comorbid insomnia and obstructive sleep apnea: challenges for clinical practice and research. J Clin Sleep Med. 2010;6(2):196–204.

    PubMed  PubMed Central  Google Scholar 

  88. Collop NA, Anderson WM, Boehlecke B, Claman D, Goldberg R, Gottlieb DJ, Hudgel D, Sateia M, Schwab R. Clinical guidelines for the use of unattended portable monitors in the diagnosis of obstructive sleep apnea in adult patients. J Clin Sleep Med. 2007;3(7):737–47.

    PubMed  Google Scholar 

  89. Raj R, Hirshkowitz M. Effect of the new Medicare guideline on patient qualification for positive airway pressure therapy. Sleep Med. 2003;4(1):29–33.

    Article  PubMed  Google Scholar 

  90. Decision Memo for Continuous Positive Airway Pressure (CPAP) Therapy for Obstructive Sleep Apnea (OSA) (CAG-00093 N). https://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=19&fromdb=true. Accessed on 19 May 2018.

  91. AGS Choosing Wisely Workgroup. American Geriatrics Society identifies five things that healthcare providers and patients should question. J Am Geriatr Soc. 2013; 61(4): 622–631. Published online 2013 Mar 7. https://doi.org/10.1111/jgs.12226.

  92. Center for Drug Evaluation and Research Medical Reviews on Suvorexant. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204569orig1s000medr.pdf. Accessed 2 Jun 2017 and 24 Mar 2018.

  93. Highlights of prescribing information. https://www.merck.com/product/usa/pi_circulars/b/belsomra/belsomra_pi.pdf. Accessed on 2 Jun 2017.

  94. Snyder E, Ma J, Svetnik V, et al. Effects of suvorexant on sleep architecture and power spectral profile in patients with insomnia: analysis of pooled phase 3 data. Sleep Med. 2016;19:93–100. https://doi.org/10.1016/j.sleep.2015.10.007 (Epub 2015 Nov 10).

    Article  PubMed  Google Scholar 

  95. Herring WJ, Connor KM, Ivgy-May N, et al. Suvorexant in patients with insomnia: results from two 3-month randomized controlled clinical trials. Biol Psychiatry. 2016;79:136–48. https://doi.org/10.1016/j.biopsych.2014.10.003.

    Article  PubMed  CAS  Google Scholar 

  96. Herring WJ, Connor KM, Snyder E, et al. Suvorexant in elderly patients with insomnia: pooled analyses of data from phase III randomized controlled clinical trials. Am J Geriatr Psychiatry. 2017;25:791–802. https://doi.org/10.1016/j.jagp.2017.03.004 (Epub 2017 Mar 8).

    Article  PubMed  Google Scholar 

  97. Vermeeren A, Vets E, Vuurman EFPM, et al. On the road driving performance the morning after bedtime use of suvorexant 15 and 30 mg in healthy elderly. Psychopharmacology. 2016;233:3341–51.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  98. Sun H, Palcza J, Card D, et al. Effects of suvorexant, an orexin receptor antagonist, on respiration during sleep in patients with obstructive sleep apnea. J Clin Sleep Med. 2016;12:9–17.

    Article  PubMed  PubMed Central  Google Scholar 

  99. Sun H, Palcza J, Rosenberg R, et al. Effects of suvorexant, an orexin receptor antagonist, on breathing during sleep in patients with chronic obstructive pulmonary disease. Respir Med. 2015;109:416–26.

    Article  PubMed  Google Scholar 

  100. Krystal AD, Durrence HH, Scharf M, et al. Efficacy and safety of doxepin 1 mg and 3 mg in a 12-week sleep laboratory and outpatient trial of elderly subjects with chronic primary insomnia. Sleep. 2010;33:1553–61 [PMID: 21102997].

    Article  PubMed  PubMed Central  Google Scholar 

  101. Scharf M, Rogowski R, Hull S, et al. Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in elderly patients with primary insomnia: a randomized, double-blind, placebo-controlled crossover study. J Clin Psychiatry. 2008;69(10):1557–64.

    Article  PubMed  CAS  Google Scholar 

  102. Lankford A, Rogowski R, Essink B, et al. Efficacy and safety of doxepin 6 mg in a four-week outpatient trial of elderly adults with chronic primary insomnia. Sleep Med. 2012;13:133–8. https://doi.org/10.1016/j.sleep.2011.09.006.

    Article  PubMed  Google Scholar 

  103. Krystal AD, Lankford A, Durrence HH, et al. Efficacy and safety of doxepin 3 and 6 mg in a 35-day sleep laboratory trial in adults with chronic primary insomnia. Sleep. 2011;34:1433–42 ([PubMed Central][PubMed]).

    PubMed  PubMed Central  Google Scholar 

  104. Highlights of prescribing information. https://www.silenor.com/hcp. Accessed on 24 Mar 2018.

  105. Monti JM, Monti D*** 2006 Overview of currently available benzodiazepine and nonbenzodiazepine hypnotics. In: Pandi-Perumal SR, Monti JM (eds) Clinical Pharmacology of Sleep. Switzerland, pp 207–223.

  106. Ancoli-Israel S, Krystal AD, McCall WV, et al. A 12-week, randomized, double-blind, placebo- controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia. Sleep. 2010;33:225–34.

    Article  PubMed  PubMed Central  Google Scholar 

  107. Monti JM, Pandi-Perumal SR. Eszopiclone: its use in the treatment of insomnia. Neuropsychiatr Dis Treat. 2007;3:441–53.

    PubMed  PubMed Central  CAS  Google Scholar 

  108. Highlights of prescribing information. http://www.lunesta.com/PostedApprovedLabelingText.pdf. Accessed on 16 June 2017.

  109. McCall WV, Erman M, Krystal AD, et al. A polysomnography study of eszopiclone in elderly patients with insomnia. Curr Med Res Opin. 2006;22:1633–42 (PubMed).

    Article  PubMed  CAS  Google Scholar 

  110. Scharf M, Erman M, Rosenberg R, et al. A 2-week efficacy and safety study of eszopiclone in elderly patients with primary insomnia. Sleep. 2005;28:720–7 (PubMed).

    Article  PubMed  Google Scholar 

  111. Tom SE, Wickwire EM, Park Y, Albrecht JS. Nonbenzodiazepine sedative hypnotics and risk of fall-related injury. Sleep. 2016;39:1009–14.

    Article  PubMed  PubMed Central  Google Scholar 

  112. Drug description, indications and dosage, side effects and interactions. https://www.rxlist.com/ambien-drug.htm#clinpharm. Accessed on 20 Feb 2018.

  113. Scharf MB, Mayleben DW, Kaffeman M, et al. Dose response effects of zolpidem in normal geriatric subjects. J Clin Psychiatry. 1991;52(2):77–83.

    PubMed  CAS  Google Scholar 

  114. Glass J, Lanctôt KL, Herrmann N et al. Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. BMJ. 2005 19;331(7526):1169.

  115. Montgomery P, Lilly J. Insomnia in the elderly. BMJ Clin Evid. 2007. Preview Abstract PMID: 19450355.

  116. Ancoli-Israel S, Walsh JK, Mangano RM, et al. Zaleplon, a novel nonbenzodiazepine hypnotic, effectively treats insomnia in elderly patients without causing rebound effects. Prim Care Companion J Clin Psychiatry. 1999;1:114–20.

    Article  PubMed  PubMed Central  Google Scholar 

  117. Roger M, Attali P, Coquelin JP. Multicenter, double-blind, controlled comparison of zolpidem and triazolam in elderly patients with insomnia. Clin Ther. 1993;15:127–36 (Preview Abstract PMID: 8458042).

    PubMed  CAS  Google Scholar 

  118. Morgan PT, Kehne JH, Sprenger KJ, et al. Retrograde effects of triazolam and zolpidem on sleep-dependent motor learning in humans. J Sleep Res. 2010;19(1 Pt 2):157–64 (Preview Abstract PMID: 19682231 ).

    Article  PubMed  Google Scholar 

  119. Ochs R, Fillingim J, Cutler N, et al. The effect of zolpidem in elderly patients with chronic insomnia. Sleep Res. 1992;21:68.

    Google Scholar 

  120. Walsh JK, Soubrane C, Roth T. Efficacy and safety of zolpidem extended release in elderly primary insomnia patients. Am J Geriatr Psychiatry. 2008;16:44–57 (PubMed).

    Article  PubMed  Google Scholar 

  121. Leger D, Scheuermaier K, Roger M. The relationship between alertness and sleep in a population of 769 elderly insomniacs with and without treatment with zolpidem. Arch Gerontol Geriatr. 1999;29:165–73 (Preview Abstract PMID: 15374069).

    Article  PubMed  CAS  Google Scholar 

  122. Monti JM, Spence DW, Buttoo K, et al. Zolpidem’s use for insomnia. Asian J Psychiatr. 2017;25:79–90 (Preview Abstract PMID: 28262178).

    Article  PubMed  Google Scholar 

  123. Emergency Department Data Year 2011 in Substance Abuse and Mental Health Services Administration. https://www.samhsa.gov/data/emergency-department-data-dawn/reports. Accessed on 24 Feb 2018.

  124. Huang CY, Chou FH, Huang YS, et al. The association between zolpidem and infection in patients with sleep disturbance. J Psychiatr Res. 2014;54:116–20. https://doi.org/10.1016/j.jpsychires.2014.03.017 Epub 2014 Mar 27.

    Article  PubMed  Google Scholar 

  125. Kao CH, Sun LM, Liang JA, et al. Relationship of zolpidem and cancer risk: a Taiwanese population-based cohort study. Mayo Clin Proc. 2012;87:430–6. https://doi.org/10.1016/j.mayocp.2012.02.012.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  126. Zammit G, Wang-Weigand S, Rosenthal M, Peng X. Effect of Ramelteon on middle-of-the-night balance in older adults with chronic insomnia. J Clin Sleep Med. 2009;5(1):34–40.

    PubMed  PubMed Central  Google Scholar 

  127. Kang DY, Park S, Rhee CW, Kim YJ, Choi NK, Lee J, et al. Zolpidem use and risk of fracture in elderly insomnia patients. J Prev Med Public Health. 2012;45:219–26. https://doi.org/10.3961/jpmph.2012.45.4.219 (Published online 2012 Jul 31).

    Article  PubMed  PubMed Central  Google Scholar 

  128. Bocca ML, Marie S, Lelong-Boulouard V, et al. Zolpidem and zopiclone impair similarly monotonous driving performance after a single nighttime intake in aged subjects. Psychopharmacology. 2011;21:699–706. https://doi.org/10.1007/s00213-010-2075-5 (Epub 2010 Nov 18).

    Article  CAS  Google Scholar 

  129. Vermeeren A, Vuurman EFPM, Leufkens TRM, et al. Residual effects of low-dose sublingual zolpidem on highway driving performance the morning after middle-of-the-night use. Sleep. 2014;37:489–96. https://doi.org/10.5665/sleep.3482 (Published online 2014 Mar 1).

    Article  PubMed  PubMed Central  Google Scholar 

  130. Roth T, Eklov SD, Drake CL, et al. Meta-analysis of on-the-road experimental studies of hypnotics: effects of time after intake, dose, and half-life. Traffic Inj Prev. 2014;15:439–45. https://doi.org/10.1080/15389588.2013.830211.

    Article  PubMed  CAS  Google Scholar 

  131. Verster JC, Volkerts ER, Schreuder AH, et al. Residual effects of middle-of-the-night administration of zaleplon and zolpidem on driving ability, memory functions, and psychomotor performance. J Clin Psychopharmacol. 2002;22(6):576–83.

    Article  PubMed  CAS  Google Scholar 

  132. Hansen RN, Boudreau DM, Ebel BE, et al. Sedative hypnotic medication use and the risk of motor vehicle crash. Am J Public Health. 2015;105:e64–9. https://doi.org/10.2105/AJPH.2015.302723 Epub 2015 Jun 11.

    Article  PubMed  PubMed Central  Google Scholar 

  133. McFarlane J, Morin CM, Montplaisir J. Hypnotics in insomnia; the experience of zolpidem. Clin Therapeutics. 2014;36:1676–701.

    Article  CAS  Google Scholar 

  134. Chen CS, Huang MF, Hwang TJ, et al. Clinical correlates of zolpidem-associated complex sleep-related behaviors: age effect. J Clin Psychiatry. 2014;75:e1314–8. https://doi.org/10.4088/JCP.13m08901.

    Article  PubMed  Google Scholar 

  135. Perlis M, Grandner M, Zee J, et al. Durability of treatment response to zolpidem with three different maintenance regimens: a preliminary study. Sleep Med. 2015;16:1160–8. https://doi.org/10.1016/j.sleep.2015.06.015 (Published online 2015 Jul 7).

    Article  PubMed  PubMed Central  Google Scholar 

  136. Roth T, Krystal A, Steinberg FJ, et al. Novel Sublingual low-dose zolpidem tablet reduces latency to sleep onset following spontaneous middle-of-the-night awakening in insomnia in a randomized, double-blind, placebo-controlled, outpatient study. Sleep. 2013;36:189–96. https://doi.org/10.5665/sleep.2370 (Published online 2013 Feb 1).

    Article  PubMed  PubMed Central  Google Scholar 

  137. Ebbens MM, Verster JC. Clinical evaluation of zaleplon in the treatment of insomnia. Nat Sci Sleep. 2010;2:115–26 (Preview Abstract PMID: 23616704 ).

    PubMed  PubMed Central  Google Scholar 

  138. Walsh JK, Fry J, Erwin CW, Scharf M, et al. Efficacy and safety of 14-day administration of zaleplon 5 mg and 10 mg for the treatment of primary insomnia. Clin Drug Invest. 1998;16:347–54.

    Article  CAS  Google Scholar 

  139. Hedner J, Yaeche R, Emilien G, et al. Zaleplon shortens subjective sleep latency and improves subjective sleep quality in elderly patients with insomnia. The Zaleplon Clinical Investigator Study Group. Int J Geriatr Psychiatry. 2000;15:704–12 (Preview Abstract PMID: 1096088 ).

    Article  PubMed  CAS  Google Scholar 

  140. Ancoli-Israel S, Richardson GS, Mangano RM, et al. Long-term use of sedative hypnotics in older patients with insomnia. Sleep Med. 2005;6:107–13 (Preview Abstract PMID: 15716214).

    Article  PubMed  Google Scholar 

  141. Walsh JK, Pollak CP, Scharf MB, et al. Lack of residual sedation following middle-of-the-night zaleplon administration in sleep maintenance insomnia. Clin Neuropharmacol. 2000;23:17–21 (Preview Abstract PMID: 10682226).

    Article  PubMed  CAS  Google Scholar 

  142. Becker PM, Somiah M. Non-benzodiazepine receptor agonists for insomnia. Sleep Med Clin. 2015;10:57–76.

    Article  PubMed  Google Scholar 

  143. Drug description Sonata. https://www.drugs.com/pro/sonata.html. Accessed on 11 Jun 2017.

  144. Donnelly K, Bracchi R, Hewitt J, Routledge PA, et al. Benzodiazepines, Z-drugs and the risk of hip fracture: a systematic review and meta-analysis. PLoS One. 2017;12(4):e01747:30. https://doi.org/10.1371/journal.pone.0174730

    Article  CAS  Google Scholar 

  145. Kilduff TS, Mendelson WB. Hypnotic medications: mechanisms of action and pharmacologic effects. In: Kryger M, Roth T, Dement WC, editors. Principles and practice of sleep medicine. 6th ed. St. Louis: Elsevier; 2017. p. 424–431.e4.

    Google Scholar 

  146. Carskadon MA, Seidel WF, Greenblatt DJ, et al. Daytime carryover of triazolam and flurazepam in elderly insomniacs. Sleep. 1982;5:361–71 (Preview Abstract PMID: 6131526).

    Article  PubMed  CAS  Google Scholar 

  147. Roehrs T, Zorick F, Wittig R, et al. Efficacy of a reduced triazolam dose in elderly insomniacs. Neurobiol Aging. 1985;6:293–6 Preview Abstract PMID: 4088425.

    Article  PubMed  CAS  Google Scholar 

  148. Piccione P, Zorick F, Lutz T, et al. The efficacy of triazolam and chloral hydrate in geriatric insomniacs. J Int Med Res. 1980;8:361–7 (Preview Abstract PMID: 6106611 ).

    Article  PubMed  CAS  Google Scholar 

  149. Ferini Strambi L, Marelli S, Zucconi M, et al. Effects of different doses of triazolam in the middle-of-the-night insomnia: a double-blind, randomized, parallel group study. J Neurol. 2017;264:1362–9.

    Article  PubMed  CAS  Google Scholar 

  150. Triazolam drug information. https://www-uptodate-com.laneproxy.stanford.edu/contents/triazolam-drug-information?source = preview&search = triazolam&anchor = F230752#F230752. Accessed on 15 Jun 2017.

  151. Maeda T, Babazono A, Nishi T, et al. Quantification of adverse effects of regular use of triazolam on clinical outcomes for older people with insomnia: a retrospective cohort study. Int J Geriatr Psychiatry. 2016;31:186–94 (Preview Abstract PMID: 26042655).

    Article  PubMed  Google Scholar 

  152. Vgontzas AN, Kales A, Bixler EO, et al. Temazepam 7.5 mg: effects on sleep in elderly insomniacs. Eur J Clin Pharmacol. 1994;46:209–13 (Preview Abstract PMID: 8070501).

    Article  PubMed  CAS  Google Scholar 

  153. Glass JR, Sproule BA, Herrmann N, et al. Effects of 2-week treatment with temazepam and diphenhydramine in elderly insomniacs: a randomized, placebo-controlled trial. J Clin Psychopharmacol. 2008;28:182–8 (Preview Abstract PMID: 18344728).

    Article  PubMed  CAS  Google Scholar 

  154. Fillingim JM. Double-blind evaluation of temazepam, flurazepam, and placebo in geriatric insomniacs. Clin Ther. 1982;4:369–80 (Preview Abstract PMID: 6121625).

    PubMed  CAS  Google Scholar 

  155. Nakra BR, Gfeller JD, Hassan R. A double-blind comparison of the effects of temazepam and triazolam on residual, daytime performance in elderly insomniacs. Int Psychogeriatr. 1992;4:45–53 (Preview Abstract PMID: 1391671).

    Article  PubMed  CAS  Google Scholar 

  156. Temazepam drug information. https://www-uptodate-com.laneproxy.stanford.edu/contents/temazepam-drug-information?source = preview&search=temazepam&anchor=F22162135#F22162135. Accessed on 16 June 2017.

  157. Kales A, Manfredi RL, Vgontzas AN, et al. Rebound insomnia after only brief and intermittent use of rapidly eliminated benzodiazepines. Clin Pharmacol Ther. 1991;49:468–76 (Preview Abstract PMID: 2015735).

    Article  PubMed  CAS  Google Scholar 

  158. Nam YS, Han JS, Kim JY, Bae WK, Lee K. Potentially inappropriate medication in Korean older adults based on 2012 Beers Criteria: a cross-sectional population based study. BMC Geriatr. 2016;16:118. https://doi.org/10.1186/s12877-016-0285-3 (Published online 2016 Jun 2).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  159. Johnson CF. Benzodiazepine and z-hypnotic prescribing for older people in primary care: a cross-sectional population based study. Br J Gen Pract. 2016;66(647):e410–5. https://doi.org/10.3399/bjgp16x685213 (Published online 2016 Apr 26).

    Article  PubMed  PubMed Central  Google Scholar 

  160. Bradley MC, Motterlini N, Padmanabhan S, et al. Potentially inappropriate prescribing among older people in the United Kingdom. BMC Geriatr. 2014;14:72. https://doi.org/10.1186/1471-2318-14-72 (Published online 2014 Jun 12).

    Article  PubMed  PubMed Central  Google Scholar 

  161. Kovačević SV, Simišić M, Rudinski SS, et al. Potentially inappropriate prescribing in older primary care patients. PLoS One. 2014;9(4):e95536. https://doi.org/10.1371/journal.pone.0095536 (Published online 2014 Apr 24).

    Article  CAS  Google Scholar 

  162. Moriarty F, Hardy C, Bennett K, Smith SM, Fahey T. Trends and interaction of polypharmacy and potentially inappropriate prescribing in primary care over 15 years in Ireland: a repeated cross-sectional study. BMJ Open. 2015;5(9):e008656. https://doi.org/10.1136/bmjopen-2015-008656 (Published online 2015 Sep 16).

    Article  PubMed  PubMed Central  Google Scholar 

  163. Barker MJ, Greenwood KM, Jackson M, Crowe SF. Persistence of cognitive effects after withdrawal from long-term benzodiazepine use: a meta-analysis. Arch Clin Neuropsychol. 2004;19(3):437–54.

    Article  PubMed  Google Scholar 

  164. Rummans TA, Davis LJ Jr, Morse RM, Ivnik RJ. Learning and memory impairment in older, detoxified, benzodiazepine- dependent patients. Mayo Clin Proc. 1993;68(8):731–7.

    Article  PubMed  CAS  Google Scholar 

  165. Zhong G, Wang Y, Zhang Y, Zhao Y. Association between benzodiazepine use and dementia: a meta-analysis. PLoS One. 2015;10(5):e0127836. https://doi.org/10.1371/journal.pone.0127836 (eCollection 2015 ).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  166. Ramelteon drug information. https://www-uptodate-com.laneproxy.stanford.edu/contents/ramelteon-drug-information?search=ramelteon%20drug%20information&source=search_result&selectedTitle=1~18&usage_type=default&display_rank=1. Accessed on 17 Jun 2017.

  167. London, 25 September 2008 Doc. Ref. EMEA/CHMP/502946/2008. Questions and answers on the withdrawal of the marketing application for 
Ramelteon. www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2010/01/WC500064662.pdf-8k-2013-07-21. Accessed on 21 Mar 2018.

  168. Roth T, Seiden D, Wang-Weigand S, et al. A 2-night, 3-period, crossover study of ramelteon’s efficacy and safety in older adults with chronic insomnia. Curr Med Res Opin. 2007;23:1005–14.

    Article  PubMed  CAS  Google Scholar 

  169. Roth T, Seiden D, Sainati S, et al. Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia. Sleep Med. 2006;7:312–8 (Preview Abstract PMID: 16709464).

    Article  PubMed  Google Scholar 

  170. Kuriyama A, Honda M, Hayashino Y. Ramelteon for the treatment of insomnia in adults: a systematic review and meta-analysis. Sleep Med. 2014;15:385–92. https://doi.org/10.1016/j.sleep.2013.11.788 (Epub 2014 Feb 8).

    Article  PubMed  Google Scholar 

  171. Zammit G, Wang-Weigand S, Rosenthal M, et al. Effect of ramelteon on middle-of-the-night balance in older adults with chronic insomnia. J Clin Sleep Med. 2009;5:34–40.

    PubMed  PubMed Central  Google Scholar 

  172. Kryger M, Wang-Weigand S, Zhang J, et al. Effect of ramelteon, a selective MT(1)/MT (2)-receptor agonist, on respiration during sleep in mild to moderate COPD. Sleep Breath. 2008;12:243–50 (Preview Abstract PMID: 1806044).

    Article  PubMed  Google Scholar 

  173. Kryger M, Roth T, Wang-Weigand S, Zhang J. The effects of ramelteon on respiration during sleep in subjects with moderate to severe chronic obstructive pulmonary disease. Sleep Breath. 2009;13(1):79–84 (Preview Abstract PMID: 18584227).

    Article  PubMed  Google Scholar 

  174. Kryger M, Wang-Weigand S, Roth T. Safety of ramelteon in individuals with mild to moderate obstructive sleep apnea. Sleep Breath. 2007;11(3):159–64 (Preview Abstract PMID: 17294232 ).

    Article  PubMed  Google Scholar 

  175. Wurtman R. Physiology and available preparations of melatonin. In UptoDate. Eds: Cooper DS, Martin KA. https://www-uptodate-com.laneproxy.stanford.edu/contents/physiology-and-available-preparations-of-melatonin?source=machineLearning&search=ramelteon&selectedTitle=7~25&sectionRank=1&anchor=H722736473#H722736473. Accessed on 27 Jun 2017.

  176. Luthringer R, Muzet M, Zisapel N, et al. The effect of prolonged-release melatonin on sleep measures and psychomotor performance in elderly patients with insomnia. Int Clin Psychopharmacol. 2009;24:239–49.

    Article  PubMed  Google Scholar 

  177. Brzezinski A, Vangel MG, Wurtman RJ, et al. Effects of exogenous melatonin on sleep: a meta-analysis. Sleep Med Rev. 2005;9:41–50 (Preview Abstract PMID: 15649737).

    Article  PubMed  Google Scholar 

  178. Buscemi N, Vandermeer B, Hooton N, et al. The efficacy and safety of exogenous melatonin for primary sleep disorders. A meta-analysis. J Gen Intern Med. 2005;20:1151–8.

    Article  PubMed  PubMed Central  Google Scholar 

  179. Lemoine P, Nir T, Laudon M, et al. Prolonged-release melatonin improves sleep quality and morning alertness in insomnia patients aged 55 years and older and has no withdrawal effects. J Sleep Res. 2007;16:372–80.

    Article  PubMed  Google Scholar 

  180. Wade A, Downie S. Prolonged-release melatonin for the treatment of insomnia in patients over 55 years. Expert Opin Investig Drugs. 2008;17(10):1567–72.

    Article  PubMed  CAS  Google Scholar 

  181. Mendelson WB. A review of the evidence for the efficacy and safety of trazodone in insomnia. J Clin Psychiatry. 2005;66:469–76.

    Article  PubMed  CAS  Google Scholar 

  182. Jaffer KY, Chang T, Vanle B, et al. Trazodone for insomnia: a systematic review. Innov Clin Neurosci. 2017;14:24–34.

    PubMed  PubMed Central  Google Scholar 

  183. Buysse DJ, Tyagi S. Clinical Pharmacology of other drugs used as hypnotics. In: Kryger M, Roth T, Dement WC, editors. Principles and practice of sleep medicine. 6th ed. St. Louis: Elsevier; 2017. p. 432–45.

    Chapter  Google Scholar 

  184. Roth AJ, McCall WV, Liguori A. Cognitive, psychomotor and polysomnographic effects of trazodone in primary insomniacs. J Sleep Res. 2011;20:552–8. https://doi.org/10.1111/j.1365-2869.2011.00928.x (Epub 2011 May 30).

    Article  PubMed  PubMed Central  Google Scholar 

  185. Montgomery I, Oswald I, Morgan K, Adam K. Trazodone enhances sleep in subjective quality but not in objective duration. Br J Clin Pharmacol. 1983;16:139–44.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  186. Camargos EF, Louzada LL, Quintas JL, et al. Trazodone improves sleep parameters in Alzheimer disease patients: a randomized, double-blind, and placebo-controlled study. Am J Geriatr Psychiatry. 2014;22:1565–74. https://doi.org/10.1016/j.jagp.2013.12.174 (Epub 2014 Jan 4).

    Article  PubMed  Google Scholar 

  187. Tanimukai H, Murai T, Okazaki N, et al. An observational study of insomnia and nightmare treated with trazodone in patients with advanced cancer. Am J Hosp Palliat Care. 2013;30(4):359–62. https://doi.org/10.1177/1049909112452334 (Epub 2012 Jul 9).

    Article  PubMed  Google Scholar 

  188. Saletu-Zyhlarz GM, Anderer P, Arnold O, Saletu B. Confirmation of the neurophysiologically predicted therapeutic effects of trazodone on its target symptoms depression, anxiety and insomnia by postmarketing clinical studies with a controlled-release formulation in depressed outpatients. Neuropsychobiology. 2003;48:194–208.

    Article  PubMed  CAS  Google Scholar 

  189. Walsh JK, Randazzo AC, Frankowski S, et al. Dose-response effects of tiagabine on the sleep of older adults. Sleep. 2005;28:673–6 (Preview Abstract PMID: 16477953).

    Article  PubMed  Google Scholar 

  190. Roth T, Wright KP, Walsh J. Effect of tiagabine on sleep in elderly subjects with primary insomnia: A randomized, double-blind, placebo- controlled study. Sleep. 2006;29:335–41.

    Article  PubMed  Google Scholar 

  191. Drug summary. http://www.pdr.net/drug-summary/Diphenhydramine-Hydrochloride–diphenhydramine-hydrochloride-1140. Accessed on 10 Jun 2017.

  192. Morin CM, Koetter U, Bastien C, et al. Valerian-hops combination and diphenhydramine for treating insomnia: a randomized placebo-controlled clinical trial. Sleep. 2005;28:1465–71.

    Article  PubMed  Google Scholar 

  193. American Geriatrics Society 2012 Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2012; 60:616-31

  194. l-Tryptophan Overview Information. https://www.webmd.com/vitamins-supplements/ingredientmono-326-L-tryptophan.aspx?activeingredientid=326&activeingredientname=L-tryptophan. Accessed on 18 Mar 2018.

  195. Spinweber CL. l-tryptophan administered to chronic sleep-onset insomniacs: late-appearing reduction of sleep latency. Psychopharmacology. 1986;90:151–5.

    Article  PubMed  CAS  Google Scholar 

  196. Brown CC, Horrom NJ, Wagman AM. Effects of l-tryptophan on sleep onset insomniacs. Waking Sleep. 1979;3:101–8.

    CAS  Google Scholar 

  197. Hartmann E, Cravens J, List S. Hypnotic effects of l-tryptophan. Arch Gen Psychiatry. 1974;31:394–7 (No abstract available).

    Article  PubMed  CAS  Google Scholar 

  198. Schneider-Helmert D, Spinweber CL. Evaluation of l-tryptophan for treatment of insomnia: a review. Psychopharmacology (Berl). 1986;89:1–7 (Preview Abstract PMID: 3090582 ).

    Article  PubMed  CAS  Google Scholar 

  199. Wyatt RJ, Engelman K, Kupfer DJ, et al. Effects of l-tryptophan (a natural sedative) on human sleep. Lancet. 1970;2:842–6 (No abstract available).

    Article  PubMed  CAS  Google Scholar 

  200. Hartmann E. Effects of l-tryptophan on sleepiness and on sleep. J Psychiatr Res. 1982–1983;17:107-13.

  201. Hudson C, Hudson SP, Hecht T, MacKenzie J. Protein source tryptophan versus pharmaceutical grade tryptophan as an efficacious treatment for chronic insomnia. Nutr Neurosci. 2005;8:121–7.

    Article  PubMed  CAS  Google Scholar 

  202. Fernstrom JD. Effects and side effects associated with the non-nutritional use of tryptophan by humans. J Nutr. 2012;142:2236S–44S. https://doi.org/10.3945/jn.111.157065 (Epub 2012 Oct 17. Review).

    Article  PubMed  CAS  Google Scholar 

  203. Kamb ML, Murphy JJ, Jones JL, et al. Eosinophilia-myalgia syndrome in l-tryptophan-exposed patients. JAMA. 1992;267:77–82.

    Article  PubMed  CAS  Google Scholar 

  204. Allen JA, Peterson A, Sufit R, et al. Post-epidemic eosinophilia-myalgia syndrome associated with L-tryptophan. Arthritis Rheum. 2011;63:3633–9.

    Article  PubMed  CAS  Google Scholar 

  205. Smith T, Kawa K, Eckl V, Morton C, Stredney R. Herbal Supplement Sales in US Increase 7.7% in 2016. Consumer preferences shifting toward ingredients with general wellness benefits, driving growth of adaptogens and digestive health products. Mark Rep 2017:115; 56-65. http://cms.herbalgram.org/herbalgram/issue115/images/HG15-Mktrpt.pdf. Accessed on 21 May 2018.

  206. Wheatley D. Kava and valerian in the treatment of stress-induced insomnia. Phytother Res. 2001;15:549–51.

    Article  PubMed  CAS  Google Scholar 

  207. Bent S, Padula A, Moore D, et al. Valerian for sleep: a systematic review and meta-analysis. Am J Med. 2006;119:1005–12. https://doi.org/10.1016/j.amjmed.2006.02.026.

    Article  PubMed  PubMed Central  Google Scholar 

  208. Taibi DM, Landis CA, Petry H, et al. A systematic review of valerian as a sleep aid: safe but not effective. Sleep Med Rev. 2007;11:209–30 (Review).

    Article  PubMed  Google Scholar 

  209. Fernández-San-Martín M, Masa-Font R, Palacios-Soler R, et al. Effectiveness of Valerian on insomnia: a meta-analysis of randomized placebo-controlled trials. Sleep Med. 2010;11:505–11. https://doi.org/10.1016/j.sleep.2009.12.009 (Epub 2010 Mar 26).

    Article  PubMed  Google Scholar 

  210. Black J, Pillar G, Hedner J, et al. Efficacy and safety of almorexant in adult chronic insomnia: a randomized placebo-controlled trial with an active reference. Sleep Med. 2017;36:86–94. https://doi.org/10.1016/j.sleep.2017.05.009 (Epub 2017 May 29).

    Article  PubMed  Google Scholar 

  211. Roth T, Black J, Cluydts R et al. Dual orexin receptor antagonist, almorexant, in elderly patients with primary insomnia: a randomized, controlled study. Sleep. 2017; 40. https://doi-org.laneproxy.stanford.edu/10.1093/sleep/zsw034. Accessed on 23 Mar 2018.

  212. Murphy P, Moline M, Mayleben D, et al. Lemborexant, a dual orexin receptor antagonist (DORA) for the treatment of insomnia disorder: results from a bayesian, adaptive, randomized, double-blind, placebo-controlled study. J Clin Sleep Med. 2017;13:1289–99. https://doi.org/10.5664/jcsm.6800.

    Article  PubMed  PubMed Central  Google Scholar 

  213. Connor KM, Mahoney E, Jackson S et al. A Phase II dose-ranging study evaluating the efficacy and safety of the orexin receptor antagonist filorexant (MK-6096) in patients with primary insomnia. Int J Neuropsychopharmacol. 2016; 19 1 August 2016, pyw022. https://doi-org.laneproxy.stanford.edu/10.1093/ijnp/pyw022. Accessed on 15 Mar 2018.

  214. Zaleplon delayed SR SK-1041. https://clinicaltrials.gov/ct2/results?cond=&term=NCT+00878553&cntry=&state=&city=&dist=. Accessed on 22 Mar 2018.

  215. Neurim pharmaceuticals announces positive phase 2 clinical trial results of piromelatine for the treatment of insomnia. http://www.neurim.com/?s=piromelatine. Accessed on 22 Mar 2018.

  216. Rosenberg R, Seiden DJ, Hull SG, et al. APD125, a selective serotonin 5-HT2A receptor inverse agonist, significantly improves sleep maintenance in primary insomnia. Sleep. 2008;31:1663–71.

    Article  PubMed  PubMed Central  Google Scholar 

  217. Arena December 2008 announcement. https://www.drugdevelopment-technology.com/projects/arena/ (for the Dec 2008 announcement). Accessed on 22 Mar 2018.

  218. Eplivanserin trial https://clinicaltrials.gov/ct2/show/NCT00805350. Accessed on 22 Mar 2018.

  219. Sanofi discontinues insomnia drug. http://www.pharmatimes.com/news/sanofi_discontinues_insomnia,_thrombosis_drugs_984072. Accessed on 21 Mar 2018.

  220. LY 2624803 trial. https://clinicaltrials.gov/ct2/show/NCT00784875. Accessed on 24 Mar 2018.

  221. Vallières A, Morin CM, Guay B. Sequential combinations of drug and cognitive behavioral therapy for chronic insomnia: an exploratory study. Behav Res Ther. 2005;43:1611.

    Article  PubMed  Google Scholar 

  222. Laudon M, Frydman-Marom A. Therapeutic effects of melatonin receptor agonists on sleep and comorbid disorders. Int J Mol Sci. 2014;15:15924–50. https://doi.org/10.3390/ijms150915924.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  223. Cheuk DK, Yeung WF, Chung KF, et al. Acupuncture for insomnia. Cochrane Database Syst Rev. 2012;9:CD005472. https://doi.org/10.1002/14651858.cd005472.pub3.

    Article  Google Scholar 

  224. Shergis JL, Ni X, Jackson ML, et al. A systematic review of acupuncture for sleep quality in people with insomnia. Complement Ther Med. 2016;26:11–20. https://doi.org/10.1016/j.ctim.2016.02.007.

    Article  PubMed  Google Scholar 

  225. Wang F, Eun-Kyoung Lee O, Feng F, et al. The effect of meditative movement on sleep quality: a systematic review. Sleep Med Rev. 2016;30:43–52.

    Article  PubMed  Google Scholar 

  226. Yang PY, Ho KH, Chen HC, et al. Exercise training improves sleep quality in middle-aged and older adults with sleep problems: a systematic review. J Physiother. 2012;58:157–63. https://doi.org/10.1016/S1836-9553(12)70106-6.

    Article  PubMed  Google Scholar 

  227. Leach MJ, Page AT. Herbal medicine for insomnia: a systematic review and meta-analysis. Sleep Med Rev. 2015;24:1–12.

    Article  PubMed  Google Scholar 

  228. Center for Drug Evaluation and Research. Application Number: 204569Orig1s000 Medical Review(s) on suvorexant. www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204569orig1s000medr.pdf. Accessed on 2 Jun 2017.

  229. Drug information. https://www.merck.com/product/usa/pi_circulars/b/belsomra/belsomra_pi.pdf. Accessed on 2 Jun 2017.

  230. Drug information. https://www.silenor.com/Content/pdf/prescribing-information.pdf. Accessed on 10 Jun 2017.

  231. Highlights of prescribing information Ambien. https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/019908s027lbl.pdf. Accessed on 10 Jun 2017.

  232. Zolpidem sublingual (Edluar) Drug description. https://www.rxlist.com/edluar-drug.htm#description Accessed on 25 Mar 2018.

  233. Center for Drug Evaluation and Research. Application Number: 022036Orig1s000. Medical Review(s) on Silenor. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022036orig1s000medr.pdf. Accessed on 10 Jun 2017 and 25 Mar 2018.

  234. Intermezzo Professional. http://www.rxlist.com/intermezzo-drug.htm. Accessed on 10 Jun 2017 and 25 Mar 2018.

  235. Highlights of prescribing information. http://myzolpimist.com/wp-content/uploads/2016/04/Zolpimist-PI-approved-final.pdf. Accessed on 10 Jun 2017 and 25 Mar 2018.

  236. Sonata Professionals. https://www.drugs.com/pro/sonata.html. Accessed on 11 Jun 2017 and 25 Mar 2018.

  237. Highlights of prescribing information. http://www.lunesta.com/PostedApprovedLabelingText.pdf. Accessed on 16 Jun 2017.

  238. Triazolam drug information. https://www-uptodate-com.laneproxy.stanford.edu/contents/triazolam-drug-information?source=preview&search=triazolam&anchor=F230752#F230752. Accessed on 15 Jun 2017.

  239. Temazepam drug information. https://www-uptodate-com.laneproxy.stanford.edu/contents/temazepam-drug-information?source=preview&search=temazepam&anchor=F22162135#F22162135. Accessed on 16 Jun 2017.

  240. Rozerem Professional. https://www.drugs.com/pro/rozerem.html. Accessed on 10 Jun 2017.

  241. Walsh JK, Roth T. Pharmacologic treatment of insomnia: benzodiazepine receptor agonists. In: Kryger M, Roth T, Dement WC, editors. Principles and practice of sleep medicine. 6th ed. St. Louis: Elsevier; 2017. p. 832–841.e4.

    Google Scholar 

  242. Krystal AD. Pharmacologic treatment of insomnia: other medications. In: Kryger M, Roth T, Dement WC, editors. Principles and practice of sleep medicine. 6th ed. St. Louis: Elsevier; 2017. p. 842–854.e5.

    Google Scholar 

  243. Shochat T, Ancoli-Israel S. Insomnia in older adults. In: Kryger M, Roth T, Dement WC, editors. Principles and practice of sleep medicine. 6th ed. St. Louis: Elsevier; 2017. p. 1503–1509.e4.

    Google Scholar 

  244. Foral P, Knezevich J, Dewan N, Malesker M. Medication-induced sleep disturbances. Consult Pharm. 2011;26:414–25. https://doi.org/10.4140/tcp.n.2011.414.

    Article  PubMed  Google Scholar 

  245. Malangu N. Drugs inducing insomnia as a side-effect. http://cdn.intechopen.com/…/InTech-Drugs_inducing_insomnia_as_an_adverse_effect.pdf. Accessed on 27 Feb 2018.

  246. Shekleton JA, Rogers NL, Rajaratnam SM. Searching for the daytime impairments of primary insomnia. Sleep Med Rev. 2010;14:47–60. https://doi.org/10.1016/j.smrv.2009.06.001 (Epub 2009 Dec 5).

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Contributions

We certify that both authors have made substantial contributions to all of the following aspects of the work: conception and planning of the work that led to the manuscript; acquisition, analysis, and interpretation of the data; drafting and/or critical revision of the manuscript for important intellectual content; and approval of the final submitted version of the manuscript.

Corresponding author

Correspondence to Christian Guilleminault.

Ethics declarations

Funding

The authors certify that no funding has been received in the conduct of this study and/or preparation of this manuscript.

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Abad, V.C., Guilleminault, C. Insomnia in Elderly Patients: Recommendations for Pharmacological Management. Drugs Aging 35, 791–817 (2018). https://doi.org/10.1007/s40266-018-0569-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40266-018-0569-8

Navigation